Rosen Law Firm Investigating Potential Securities Claims Against Aldeyra Therapeutics

Investors Who Suffered Losses Encouraged to Contact Firm About Their Rights

Mar. 22, 2026 at 10:34pm

Got story updates? Submit your updates here. ›

The Rosen Law Firm, a global investor rights law firm, has announced an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) following allegations that the company may have issued materially misleading business information to the investing public.

Why it matters

This investigation comes after Aldeyra received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, stating a lack of substantial evidence demonstrating the drug's effectiveness in treating dry eye disease. The news caused Aldeyra's stock price to plummet 70.7% on March 17, 2026, potentially resulting in significant losses for investors.

The details

According to the announcement, the Rosen Law Firm is preparing a class action lawsuit seeking recovery of investor losses. The firm is encouraging investors who purchased Aldeyra securities to join the prospective class action, which can be done through the firm's website or by contacting the firm directly.

  • On March 17, 2026, Aldeyra filed an 8-K with the SEC announcing the FDA's Complete Response Letter.
  • On March 17, 2026, Aldeyra's stock price fell $2.99 per share, or 70.7%, to close at $1.24 per share.

The players

Rosen Law Firm

A global investor rights law firm that specializes in securities class actions and shareholder derivative litigation.

Aldeyra Therapeutics, Inc.

A biotechnology company focused on the development of novel therapies for the treatment of immune-mediated diseases.

U.S. Food and Drug Administration (FDA)

The federal agency responsible for regulating and supervising the safety of food, drugs, and other products in the United States.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel.”

— Phillip Kim, Attorney

What’s next

The judge in the case will decide on whether to allow the class action lawsuit to proceed.

The takeaway

This investigation highlights the importance for investors to carefully research and select qualified legal counsel when pursuing potential securities claims, as the experience and track record of the law firm can be crucial to the success of the case.